1) As EGFR, KRAS, and BRAF mutations are clinically relevant, mainly predictive biomarkers in colorectal and lung carcinomas, we aimed to evaluate by NGS and routinely used real-time PCR (RT-PCR) methods the feasibility of NGS for analysis of these mutations. This evidence concerns the gene EGFR and lung carcinoma.